Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients — PCA  

Acute Myeloid Leukemia Clinical Trial

Official title: Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine Patient Controlled Analgesia (PCA) for Mucositis Pain in Pediatric Patients. A Prospective Randomized Double Blinded Clinical Trial

Status Completed

Clinical Trial Summary

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled analgesia (PCA) for mucositis pain in pediatric cancer patients

Clinical Trial Description

The investigators will compare between using of PCA Morphine (Group A) and using of PCA Nalbuphine (Group B) in the following items over the first 7 days of initiation:

1. Pain intensity VAS every 12 hours and during the performing of mouth care for each patient over the first 7 days.

2. Total opioid consumptions for each patient every 24 hours and the total consumption of the entire 7 days since initiation.

3. Number of active and total pushes of PCA buttons every 24 hours and the sum up of the active and total pushes of PCA buttons for each patient over the 7 days.

4. Patient satisfaction at the end of the 7 days. Patient satisfaction score PSS was assessed using a linear scale where 0=very satisfied; 10=very dissatisfied (14).

5. Serious adverse events. (Nausea and vomiting, pruritus, respiratory depression, urinary retention, sedation, bradycardia, hypotension). ;

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Mucositis
• Stem Cell Leukemia

• NCT number: NCT03825887
• Study type: Interventional
• Source: Children's Cancer Hospital Egypt 57357
• Status: Completed
• Phase: Phase 3
• Start date: February 1, 2018
• Completion date: December 31, 2020